Last reviewed: June 4, 2026

Last updated: June 4, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

In 2021, the FDA approved semaglutide as a dedicated weight loss medication, marking a turning point in obesity treatment. This GLP-1 receptor agonist works by regulating appetite signals in the brain and slowing digestion, helping patients achieve meaningful weight reduction when combined with lifestyle changes. Understanding how this medication works and who benefits most can help guide your personalized treatment decisions.

FDA Approval Status of Semaglutide for Weight Management

The FDA granted approval to semaglutide under the brand name Wegovy in June 2021 for chronic weight management in adults. This approval was based on the STEP trials, which demonstrated that patients receiving semaglutide lost approximately 15% of their body weight over 68 weeks—nearly three times more than those on placebo alone. The medication represents a significant advancement for individuals who have struggled with traditional diet and exercise approaches.

Semaglutide operates as a GLP-1 receptor agonist, a class of drugs originally developed for type 2 diabetes management. By activating GLP-1 receptors throughout the body, the medication reduces hunger signals, increases satiety, and improves metabolic function. These mechanisms work together to help patients consume fewer calories while experiencing better control over food cravings throughout the day.

Clinical Evidence Supporting Semaglutide Weight Loss Results

The STEP clinical trial program included four randomized controlled studies involving over 4,500 participants across diverse populations. Participants who received weekly semaglutide injections experienced average weight loss ranging from 10% to 18% of their starting body weight, depending on the specific dose and individual factors. These results were sustained over the trial duration, with many patients maintaining their weight loss achievements throughout the study period.

Beyond weight reduction, semaglutide demonstrated cardiovascular benefits in the SELECT trial, which enrolled patients with obesity or overweight status plus established heart disease or high cardiovascular risk. Participants on semaglutide showed a 20% reduction in major adverse cardiovascular events compared to placebo, indicating benefits that extend beyond the scale. This evidence supports semaglutide as a treatment option for patients whose weight contributes to metabolic and cardiovascular complications.

How Semaglutide Works in the Body for Weight Control

Semaglutide mimics glucagon-like peptide-1, a natural hormone that regulates blood sugar and appetite. When injected subcutaneously once weekly, the medication reaches peak concentration within one to three days and maintains steady levels throughout the week. This consistent presence in your system provides sustained appetite suppression and metabolic improvements without requiring daily dosing.

The medication activates GLP-1 receptors in multiple locations: the hypothalamus controls hunger and fullness signals, the brainstem modulates appetite perception, and the gastrointestinal tract slows stomach emptying. Together, these actions create a powerful appetite-suppressing effect while reducing cravings for high-calorie foods. Most patients report feeling fuller on smaller portions and experiencing reduced food preoccupation within the first few weeks of treatment.

Accessing Semaglutide Through PlexusDx: Compounded vs. Brand Options

PlexusDx provides compounded semaglutide injections starting at $149 per month through licensed 503A compounding pharmacies, offering an accessible alternative to brand-name Wegovy while maintaining the same active ingredient and mechanism. Compounded medications are prepared by licensed pharmacists who follow FDA guidelines and quality standards, ensuring safety and efficacy equivalent to brand versions. PlexusDx serves all 50 states without requiring insurance, membership fees, or prior authorization delays.

The pricing advantage of compounded semaglutide through PlexusDx makes this FDA-approved therapy financially accessible to more patients. Your dose may need to go up as your body adjusts and your treatment progresses, but your price won't increase—PlexusDx maintains flat monthly pricing regardless of dose level. Additionally, PlexusDx offers HSA and FSA eligibility, allowing you to use pre-tax healthcare dollars to cover treatment costs and maximize your budget.

Genetic Personalization and Semaglutide Response Optimization

Individual genetic differences influence how effectively semaglutide works for each person. PlexusDx's Precision Peptide Genetic Test identifies key variants in the GLP1R gene (rs6923761) and related metabolic pathways that predict treatment response and optimal dosing strategies. This genetic assessment, available as a $99 add-on after your first month of treatment, maps 14 distinct peptide pathways and provides insights into 150+ genetic factors affecting your weight loss journey.

Beyond GLP-1 genetics, the test examines variants in genes like MC4R (rs17782313), which regulates energy expenditure, and FTO (rs9939609), which influences fat mass predisposition. Understanding your unique genetic profile allows PlexusDx to personalize your treatment approach, potentially predicting which patients may benefit from combination therapies like GLP-Squared (semaglutide plus tirzepatide) or alternative protocols. This precision-medicine approach increases the likelihood of achieving your weight loss goals while minimizing trial-and-error dosing.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is semaglutide FDA-approved specifically for weight loss in people without diabetes?

Yes. The FDA approved semaglutide (Wegovy) in 2021 for chronic weight management in adults with obesity or overweight status plus weight-related conditions, independent of diabetes status. Clinical trials demonstrated sustained weight loss of 10–18% over 68 weeks compared to placebo.

How much weight can I expect to lose with semaglutide treatment?

Individual results vary, but clinical trials showed average weight loss of 10–18% of starting body weight over approximately 68 weeks. Results depend on your genetics, lifestyle adherence, starting weight, and dose tolerance. PlexusDx's Precision Peptide Genetic Test can help predict your likely response trajectory.

How does PlexusDx pricing compare to brand-name Wegovy?

PlexusDx compounded semaglutide injections start at $149 per month through licensed 503A pharmacies, typically costing significantly less than brand Wegovy without sacrificing quality. Your dose may increase over time, but PlexusDx maintains flat monthly pricing—meaning no price increases as you adjust your dose.

Are compounded semaglutide injections from PlexusDx as safe as brand-name versions?

Yes. PlexusDx sources from licensed 503A compounding pharmacies that follow strict FDA guidelines, quality standards, and sterility protocols matching pharmaceutical-grade standards. The active ingredient and mechanism are identical to brand versions, providing equivalent safety and efficacy.

Can genetic testing predict how well semaglutide will work for me personally?

Yes. PlexusDx's Precision Peptide Genetic Test identifies variants in your GLP1R gene and 13 other peptide pathways that influence semaglutide response and optimal dosing.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves